Page 45 - Demo

ANALESRANFwww.analesranf.com18. Jastreboff AM, Aronne LJ, Ahmad NN, WhartonS, Connery L, Alves B, et al. Tirzepatide OnceWeekly for the Treatment of Obesity. N EnglJ Med. 2022 Jul 21;387(3):205%u201316.19. Campbell JE, Drucker DJ. Pharmacology,physiology, and mechanisms of incretinhormone action. Cell Metab. 2013 Jun4;17(6):819%u201337.20. Andreasen CR, Andersen A, Knop FK, Vilsb%u00f8ll T.Understanding the place for GLP-1RAtherapy: Translating guidelines for treatmentof type 2 diabetes into everyday clinicalpractice and patient selection. Diabetes,Obes Metab. 2021 Sep 14;23(S3):40%u201352.21. S%u00e1nchez Muniz FJ. The %u201cHollywood drug%u201d: Atreatment for obesity and type 2 diabetes,not valid for everyone. An la Real Acad NacFarm. 2025 Mar 31;(91(01)):7%u201315.22. Frias JP, Deenadayalan S, Erichsen L, Knop FK,Lingvay I, Macura S, et al. Efficacy andsafety of co-administered once-weeklycagrilintide 2%u00b74 mg with once-weeklysemaglutide 2%u00b74 mg in type 2 diabetes: amulticentre, randomised, double-blind,active-controlled, phase 2 trial. Lancet.2023 Aug;402(10403):720%u201330.23. Van Namen M, Prendergast L, Peiris C.Supervised lifestyle intervention for peoplewith metabolic syndrome improves outcomesand reduces individual risk factors ofmetabolic syndrome: A systematic reviewand meta-analysis. Metabolism. 2019 Dec1;101.24. Huttunen-Lenz M, Hansen S, Christensen P,Larsen TM, Sand%u00f8-Pedersen F, Drummen M,et al. PREVIEW study%u2014Influence of abehavior modification intervention (PREMIT)in over 2300 people with pre-diabetes:Intention, self-efficacy and outcomeexpectancies during the early phase of alifestyle intervention. Psychol Res BehavManag. 2018;11:383%u201394.25. Verduci E, Banderali G, Di Profio E, Vizzuso S,Zuccotti G, Radaelli G. Effect of individualversus collective-based nutritional-lifestyleintervention on the atherogenic index ofplasma in children with obesity: arandomized trial. Nutr Metab (Lond). 2021Dec 1;18(1).26. Ramos-L%u00f3pez O, Milagro FI, Riezu-Boj JI,Martinez JA. Epigenetic signaturesunderlying inflammation: an interplay of6. Heymsfield SB, Wadden TA. Mechanisms,Pathophysiology, and Management ofObesity. N Engl J Med. 2017 Jan19;376(3):254%u201366.7. Rosales Ricardo Y. Antropometr%u00eda en eldiagn%u00f3stico de pacientes obesos; unarevisi%u00f3n. Nutr Hosp. 2012;27(6):1803%u20139.8. Garc%u00eda-Quismondo Fern%u00e1ndez A, Monereo S.Metabolically healthy obese vs.metabolically unhealthy obese. Inst Espa%u00f1ay Real Acad Nac Farm. 2018;(IV y V CursosAvanzados sobre Obesidad y S%u00edndromeMetab%u00f3lico. S%u00e1nchez-Muniz FJ.):293%u2013303.9. Rubino F, Cummings DE, Eckel RH, Cohen R V,Wilding JPH, Brown WA, et al. Definition anddiagnostic criteria of clinical obesity. LancetDiabetes Endocrinol. 2025 Mar;13(3):221%u201362.10. Obesity [Internet]. [consultado el 2021 Feb 19].https://www.who.int/healthtopics/obesity#tab=tab_111. Finkelstein EA, Khavjou OA, Thompson H,Trogdon JG, Pan L, Sherry B, et al. Obesityand severe obesity forecasts through 2030.Am J Prev Med. 2012 Jun;42(6):563%u201370.12. Wang YC, McPherson K, Marsh T, Gortmaker SL,Brown M. Health and economic burden of theprojected obesity trends in the USA and theUK. Lancet (London, England).2011;378(9793):815%u201325.13. World Obesity Federation Global ObesityObservatory [Internet]. [consultado el2022Apr 22]. https://data.worldobesity.org/14. Ballesteros-Pomar MD, Rodr%u00edguez-Urgell%u00e9s E,Sastre-Bel%u00edo M, Mart%u00edn-Lorenzo A, SchneckeV, Seg%u00fa L, et al. Assessment of the PotentialClinical and Economic Impact of Weight Lossin the Adult Population with Obesity andAssociated Comorbidities in Spain. Adv Ther.2025 Feb 1;42(2):1265%u201382.15. Ordov%u00e1s JM, Ferguson LR, Tai ES, Mathers JC.Science and Politics of Nutrition:Personalised nutrition and health. BMJ.2018;361.16. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1receptor agonists in the treatment of type 2diabetes %u2013 state-of-the-art. Mol Metab. 2021Apr 1;46.17. Rodr%u00edguez PJ, Goodwin Cartwright BM, Gratzl S,Brar R, Baker C, Gluckman TJ, et al.Semaglutide vs Tirzepatide for Weight Lossin Adults With Overweight or Obesity. JAMAIntern Med. 2024 Sep 1;184(9):1056.167 An. R.Acad. Farm.Vol. 91. n%u00ba 2 (2025) %u00b7 pp. 151-172Tratamiento diet%u00e9tico de la obesidad personalizado y de precisi%u00f3n: Revisi%u00f3n narrativaFernando Vidal-Ostos; Julia %u00c1lvarez et al.